We have updated our Online Services Terms of Use and Privacy Policy. See our Cookies Notice for information concerning our use of cookies and similar technologies. By using this website or clicking “I ACCEPT”, you consent to our Online Services Terms of Use.
Find University Hospitals Doctors
Leila Hojat, MD

Leila Hojat, MD

  • Specialty: Infectious Disease
  • Primary Location: 11100 Euclid Ave (0 mi.)
    Other Locations
  • Languages Spoken: English, Farsi, Spanish

Office Locations

DO Mather 1600 (0 mi.)

11100 Euclid Ave
Mather Ste 1600
Cleveland, OH 44106
216-844-1709

Biography: Leila Hojat, MD

Titles

  • Assistant Professor, CWRU School of Medicine

Certifications & Memberships

  • Infectious Disease - American Board of Internal Medicine
  • Pediatrics - American Board of Pediatrics
  • Internal Medicine - American Board of Internal Medicine

Education

Fellowship | Infectious Diseases
Infectious Diseases - University Of Colorado Hospital (2017 - 2019)

Residency | Internal Medicine/Pediatrics
Internal Medicine/Pediatrics - Metrohealth Medical Center (2013 - 2017)

Other Education
Case Western Reserve University (2022)

Medical Education
University Of Cincinnati College Of Medicine (2013)

Undergraduate
John Carroll University (2009)

About

Leila Hojat, MD is a med-peds residency trained adult Infectious Diseases academic physician. She serves as the Director of Antimicrobial Stewardship at University Hospitals Cleveland Medical Center in addition to attending on general and COVID ID consult services. Her clinical interests include novel antimicrobial agents, rapid diagnostics, and health disparities.

Related Blog Articles

antibiotic resistant bacteria illustration

'Superbugs' Are Surging and So Is Antibiotic Resistance

A surge of antibiotic-resistant “superbugs” has emerged since the COVID-19 pandemic. Learn how exerts are fighting these hard-to-treat infections.

Industry Relationships

University Hospitals is committed to transparency in our interactions with industry partners, such as pharmaceutical, biotech, or medical device companies. At UH, we disclose practitioner and their family members’ ownership and intellectual property rights that are or in the process of being commercialized. In addition, we disclose payments to employed practitioners of $5,000 or more from companies with which the practitioners interact as part of their professional activities. These practitioner-industry relationships assist in developing new drugs, devices and therapies and in providing medical education aimed at improving quality of care and enhancing clinical outcomes. At the same time, UH understands that these relationships may create a conflict of interest. In providing this information, UH desires to assist patients in talking with their practitioners about industry relationships and how those relationships may impact their medical care.

UH practitioners seek advance approval for certain new industry relationships. In addition, practitioners report their industry relationships and activities, as well as those of their immediate family members, to the UH Office of Outside Interests annually. We review these reports and implement management plans, as appropriate, to address conflicts of interest that may arise in connection with medical research, clinical care and purchasing decisions.

View UH’s policy (PDF) on practitioner-industry relationships.

As of December 31, 2016, Leila Hojat did not disclose any Outside Relationships with Industry.